7,115 Johnson & Johnson $JNJ Shares Bought by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 607,323 shares of the company’s stock after purchasing an additional 7,115 shares during the period. Johnson & Johnson makes up about 1.1% of Sumitomo Mitsui DS Asset Management Company Ltd’s holdings, making the stock its 17th largest position. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Johnson & Johnson were worth $160,783,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Altium Investment Strategies LLC acquired a new position in Johnson & Johnson during the third quarter worth $209,000. CWA Asset Management Group LLC boosted its position in Johnson & Johnson by 1.1% during the third quarter. CWA Asset Management Group LLC now owns 98,737 shares of the company’s stock worth $26,140,000 after purchasing an additional 1,042 shares in the last quarter. Single Point Partners LLC grew its holdings in Johnson & Johnson by 3.6% in the third quarter. Single Point Partners LLC now owns 1,309 shares of the company’s stock valued at $347,000 after purchasing an additional 45 shares during the last quarter. Worth Financial Advisory Group LLC grew its holdings in Johnson & Johnson by 4.4% in the third quarter. Worth Financial Advisory Group LLC now owns 2,482 shares of the company’s stock valued at $657,000 after purchasing an additional 105 shares during the last quarter. Finally, Blue Zone Wealth Advisors LLC increased its position in shares of Johnson & Johnson by 3.1% in the third quarter. Blue Zone Wealth Advisors LLC now owns 1,671 shares of the company’s stock valued at $442,000 after buying an additional 51 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson raised its 2026 outlook, calling for approximately $101.2 billion in sales at the midpoint and adjusted earnings per share of $11.05–$11.15. Its latest quarter also modestly exceeded expectations, with adjusted EPS of $2.59 versus the $2.53 consensus and revenue of $25.40 billion. Johnson & Johnson Drugs Lift Guidance, but Is 23 Times Earnings Fair?
• Positive Sentiment: The company extended its dividend-growth streak to 64 consecutive years, supporting its appeal to income-focused investors despite weaker reported earnings. Johnson & Johnson’s Profit Fell 96% Year-Over-Year
• Positive Sentiment: MedTech momentum includes the U.S. launch of the Shockwave C2 Aero Fly coronary IVL catheter, designed to reduce treatment time and strengthen J&J’s cardiovascular-device franchise. TD Cowen reiterated a Buy rating with a $300 price target. Johnson & Johnson Launches Next-Generation Shockwave Catheter

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on JNJ shares. Evercore set a $300.00 price target on Johnson & Johnson in a research note on Tuesday. The Goldman Sachs Group reiterated a “buy” rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. Argus set a $300.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 29th. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $257.64 on Thursday. The company has a market cap of $620.90 billion, a PE ratio of 39.04, a price-to-earnings-growth ratio of 2.56 and a beta of 0.21. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The company has a 50-day simple moving average of $265.46 and a 200-day simple moving average of $249.94.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s payout ratio is 81.21%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 64,515 shares of company stock worth $17,271,766. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.